• Alnylam Pharmaceuticals average return on tangible equity for 2023 was 556.48, a 208.06% decline from 2022.
• Alnylam Pharmaceuticals average return on tangible equity for 2022 was -514.98, a 458.06% decline from 2021.
• Alnylam Pharmaceuticals average return on tangible equity for 2021 was -92.28, a 47.2% increase from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.